Solving Sovaldi: David Harlow Talks Value-Based Payment with Cyndy Nayer
We have been deluged with stories about the $100-a-pill medication for Hepatitis C. Is it really worth $87,000? (Well, it's cheaper than a $600,000 liver transplant.) I had the opportunity to speak with Cyndy Nayer, of the Center of Health Engagement, about the issues surrounding this drug and its use, value-based approaches to payment, and the question of whether we are able to solve this problem in our current environment at all.Given the nature of employment-based health insurance (even in an Obamacare world), and even given steps taken in the right direction by commercial ACOs, I have serious questions about whether long-term value-based payment structures can work (i.e., paying for a 90-day supply of a medication over three years), but Cyndy is more optimistic. If big pharma, payors and the health care delivery system are able to collaborate around this issue, then maybe there's hope for us after all.
Have a listen to our conversation (it clocks in at about 25 minutes; transcript to be posted as soon as it is available).
Listen here............
Related
Reducing the cost of new hepatitis C drugs
An index of articles pointing the reader to the current controversy over the high price of Sovaldi
How Can We Tell if Patients are Still at Risk for HCC after HCV Therapy?
No comments:
Post a Comment